questionText: To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of ensuring that a permanent access agreement is reached for Brineura as a treatment for patients with neuronal ceroid lipofuscinosis type 2 (CLN
answerText: The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether cerliponase alfa, also known as Brineura, can be recommended for routine NHS funding, considering real-world evidence ...
heading: Cerliponase Alfa